Date | Time | Source | Headline | Symbol | Company |
06/07/2024 | 2:15PM | iHub Newswire | FeaturedDaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio | | |
05/30/2024 | 9:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ROIV | Roivant Sciences Ltd |
05/30/2024 | 4:46PM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ROIV | Roivant Sciences Ltd |
05/30/2024 | 7:45AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ROIV | Roivant Sciences Ltd |
05/30/2024 | 7:15AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ROIV | Roivant Sciences Ltd |
05/30/2024 | 7:00AM | GlobeNewswire Inc. | Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
05/22/2024 | 9:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ROIV | Roivant Sciences Ltd |
05/22/2024 | 9:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ROIV | Roivant Sciences Ltd |
05/22/2024 | 9:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ROIV | Roivant Sciences Ltd |
05/16/2024 | 4:05PM | GlobeNewswire Inc. | Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
04/02/2024 | 7:00AM | GlobeNewswire Inc. | Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million | NASDAQ:ROIV | Roivant Sciences Ltd |
03/26/2024 | 6:22PM | PR Newswire (US) | Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 | NASDAQ:ROIV | Roivant Sciences Ltd |
02/13/2024 | 7:00AM | GlobeNewswire Inc. | Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
01/30/2024 | 4:05PM | GlobeNewswire Inc. | Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
12/20/2023 | 4:30PM | GlobeNewswire Inc. | Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease | NASDAQ:ROIV | Roivant Sciences Ltd |
12/14/2023 | 9:00AM | GlobeNewswire Inc. | Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease | NASDAQ:ROIV | Roivant Sciences Ltd |
11/28/2023 | 7:00AM | GlobeNewswire Inc. | Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential | NASDAQ:ROIV | Roivant Sciences Ltd |
11/27/2023 | 8:00AM | GlobeNewswire Inc. | Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus | NASDAQ:ROIV | Roivant Sciences Ltd |
11/13/2023 | 7:00AM | GlobeNewswire Inc. | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
11/10/2023 | 8:00AM | GlobeNewswire Inc. | Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors | NASDAQ:ROIV | Roivant Sciences Ltd |
10/30/2023 | 5:30PM | GlobeNewswire Inc. | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 | NASDAQ:ROIV | Roivant Sciences Ltd |
10/23/2023 | 3:41PM | Dow Jones News | Trending: Roche to Buy Telavant From Roivant and Pfizer | NASDAQ:ROIV | Roivant Sciences Ltd |
10/23/2023 | 7:18AM | IH Market News | Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more | NASDAQ:ROIV | Roivant Sciences Ltd |
10/23/2023 | 4:16AM | Dow Jones News | Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update | NASDAQ:ROIV | Roivant Sciences Ltd |
10/23/2023 | 1:50AM | Dow Jones News | Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal | NASDAQ:ROIV | Roivant Sciences Ltd |
10/23/2023 | 1:00AM | GlobeNewswire Inc. | Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | NASDAQ:ROIV | Roivant Sciences Ltd |
10/13/2023 | 8:00AM | GlobeNewswire Inc. | Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer | NASDAQ:ROIV | Roivant Sciences Ltd |
09/26/2023 | 6:00AM | GlobeNewswire Inc. | Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results | NASDAQ:ROIV | Roivant Sciences Ltd |
09/11/2023 | 8:00AM | GlobeNewswire Inc. | Roivant Announces Completion of Redemption of its Outstanding Warrants | NASDAQ:ROIV | Roivant Sciences Ltd |
08/17/2023 | 4:05PM | GlobeNewswire Inc. | Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants | NASDAQ:ROIV | Roivant Sciences Ltd |